New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy
MiraDx, a molecular diagnostics company focused on germline genetic testing to personalize cancer treatment, announced a new analysis has been published in the Journal of Health Economics and Outcomes Research demonstrating that the PROSTOX™ ultra test can deliver substantial long-term economic and quality-of-life benefits for patients and the healthcare system.
MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy
MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, announced today that its PROSTOX ultra test is now available for ordering in the United States. The test, which helps identify localized prostate cancer patients at increased risk of developing side effects from stereotactic body radiation therapy (SBRT), has already helped over 3,500 patients as part of an Early Access Program involving select academic centers and private practices.
MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 that Confirms that Prostate Cancer Patients Identified as High-risk with PROSTOX™ ultra for SBRT Toxicity Can Safely Receive Other Radiation Regimens
MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, announced today a study from UCLA that will be presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 27 to October 1, 2025, in San Francisco, Calif.
MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 that Highlights the Role of MicroRNA-based Genetic Signatures in Predicting Radiation and Immunotherapy Treatment-Related Outcomes
MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, today announced two studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago, IL. The studies, run in partnership with UCLA, highlight MiraDx’s platform as a predictive tool for treatment toxicity and response to modern cancer immunotherapies.
MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer
MiraDx, a molecular diagnostics company advancing personalized medicine through novel germline biomarkers, announced a groundbreaking study published in the journal Clinical Cancer Research, validating previous findings that its PROSTOX ultra test can predict long-term side effects from radiation therapy for prostate cancer, prior to starting treatment. Led by researchers at UCLA’s Department of Radiation Oncology, the study confirms the effectiveness of PROSTOX ultra, the first test capable of predicting long-term radiation side effects based on a patient’s unique genetic profile. The findings reinforce that radiation toxicity is a biologically unique response for each patient, underscoring the potential to personalize and improve cancer treatment using genetics.
